Brussels-based umbrella organization coordinating European brain research strategy, connecting patient groups, scientists, and industry across neurodegenerative and neurological disorders.
The European Brain Council is a Brussels-based umbrella organization that coordinates brain research strategy across Europe, bringing together patient groups, scientific societies, and industry players in neuroscience. Their core work is aligning national and European research agendas on brain disorders — from Alzheimer's and dementia to ALS and metabolic comorbidities. They act as a policy and coordination hub rather than a lab: they don't conduct primary research themselves but shape research priorities, facilitate multi-stakeholder engagement, and ensure patient perspectives are embedded in brain research programs. Their flagship H2020 project EBRA (European Brain Research Area) exemplifies this role — mapping and connecting fragmented brain research initiatives across Europe.
Led the EBRA project (EUR 1.2M) to align European brain research agendas, and participated in MULTI-ACT on research impact frameworks and PRIME on brain-metabolic comorbidities.
Involved in AD Detect-Prevent (presymptomatic Alzheimer's detection via digital tools), PRIME (dementia-metabolic multimorbidity), and BRAINTEASER (AI-based ALS/MS home care).
BRAINTEASER applies AI and decision support systems for ALS/MS home care; AD Detect-Prevent uses gamification and digital brain games for cognitive decline detection.
MULTI-ACT developed collective research impact frameworks to foster genuine engagement of patients and society in brain research.
PRIME investigates insulin resistance links to dementia, Alzheimer's, compulsivity, and autism — bridging metabolic and brain disorder domains.
In their early H2020 period (2018), EBC focused on foundational neuroscience tools and early detection — projects involved brain-on-chip technology, 3D bioprinting, gamification for cognitive decline screening, and presymptomatic Alzheimer's detection. By 2020-2021, their focus shifted toward interdisciplinary approaches connecting brain disorders with metabolic conditions (diabetes, obesity) and toward AI-driven personalized healthcare for neurological patients at home. This evolution shows a move from basic research coordination toward applied, patient-facing digital health solutions with a growing emphasis on comorbidity and real-world care settings.
EBC is moving from pure research coordination toward applied digital health and AI for neurological conditions, with increasing attention to how metabolic disorders interact with brain diseases — expect future projects at the neuro-metabolic and digital therapeutics intersection.
EBC primarily joins consortia as a participant (4 of 6 projects) but has demonstrated coordination capability with EBRA, their largest project by far (EUR 1.2M). With 64 unique partners across 17 countries, they operate as a well-connected network hub — consistent with their role as a European umbrella organization. Their value in a consortium is not technical execution but rather their ability to mobilize patient networks, align research communities, and provide policy-level legitimacy to brain research initiatives.
EBC has collaborated with 64 unique partners across 17 countries, reflecting a broad pan-European network. As a Brussels-based umbrella body, their connections span universities, hospitals, patient organizations, and industry across Western and Southern Europe.
EBC occupies a rare niche: they are not a research performer but a research organizer for the entire European brain disorder community. This makes them uniquely valuable as a consortium partner when a project needs credibility with patient organizations, alignment with EU brain research policy, or dissemination reach across the neuroscience community. For any project touching neurodegeneration, mental health, or brain-related digital health, EBC brings an unmatched network of scientific societies and patient advocacy groups that no single university or company can replicate.
